Addition by subtraction: AstraZeneca continues to slim down

It is selling the North American rights to its anti-psychotic products Seroquel and Seroquel XR. This is part of the Anglo-Swedish giant's focus on its core R&D portfolio and bunch blockbusters it owns

AstraZeneca -

As part of its focus on its core drugs portfolio, AstraZeneca PLC (LON:AZN) is divesting the US and Canadian rights to its anti-psychotic products Seroquel and Seroquel XR in a deal worth up to US$41mln.

The buyer is a company called Cheplapharm, a German speciality pharma business, which is handing over an initial US$35mln, followed by a “sales-contingent” payment of up to US$6mln.

North American revenues from the two versions of the drug, used to treat schizophrenia and bipolar, were US$115mln last year.

 “This divestment supports our strategy of reducing the number of mature medicines to enable reinvestment in our main therapy areas,” said Ruud Dobber, vice president of AZ’s biopharmaceuticals unit.

In October, Cheplapharm agreed to buy the European and Russian rights to Seroquel for an upfront US$178mln. Both formulations have lost patent protection.

Quick facts: AstraZeneca

Price: 8676 GBX

Market: LSE
Market Cap: £113.85 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


S-Ventures eyes 'opportunities to scale' in the wellness sector after...

S-Ventures PLC's (LON:SVEN) Scott Livingston talks to Proactive about their latest listing on the AQUIS and their plan to create value for investors and other stakeholders by capitalising on the investment opportunities in the growing wellbeing sector. Livingston goes on to explain their...

18 hours, 33 minutes ago

2 min read